肌肉扭傷市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球肌肉痙攣發育不良市場預計將從 2025 年的 36.5 億美元大幅成長至 2031 年的 54.1 億美元，複合年成長率為 6.78%。

該市場涵蓋一系列藥物療法和醫療設備專門用於緩解與各種中樞神經系統疾病相關的非自主性肌肉收縮。其成長的主要驅動力是全球慢性神經系統疾病（例如腦性麻痹和中風）發病率的不斷上升，這些疾病需要持續的治療管理，以改善患者的運動功能和生活品質。

例如，根據國際多發性硬化症聯盟的報告，到2024年，全球將有約290萬多發性硬化症患者，這將對有效的抗癲癇藥物產生持續的需求。然而，進一步拓展市場的主要障礙是肉毒桿菌注射和鞘內Baclofen幫浦等先進治療方法的高昂費用。這些高昂的費用，加上開發中國家不完善的報銷政策，使得患者無法獲得必要的治療，迫使醫療服務提供者選擇價格更低但療效較差的口服非專利藥。因此，這些地區的收入潛力受到限制。

市場促進因素

推動肌肉攣縮市場擴張的主要因素是慢性神經系統疾病的日益普遍，這些疾病通常會在中樞神經系統損傷後導致癲癇發作。中風和創傷性腦損傷等疾病會擾亂正常的神經訊號傳導，因此迫切需要有效的長期管理策略來預防永久性肌肉攣縮。根據世界衛生組織 (WHO) 2024 年 3 月的一項調查，全球整體約有 34 億人患有神經系統疾病，這些疾病是導致殘疾的主要原因，因此對治療性介入的需求將持續存在。

例如，根據美國國家脊髓損傷統計中心的估計，到2024年，美國將有約30.5萬例脊髓損傷病例，而這些患者群體高度依賴持續的抗驚厥治療。此外，肉毒桿菌毒素製劑的日益普及是重要的次要促進因素，顯示臨床治療正從全身性口服藥物轉向標靶局部治療。這些生物製藥擴大被專科醫生用於治療難治性痙攣，因為它們能夠提供精準的肌肉鬆弛效果，同時降低全身性副作用的風險。艾伯維公司2024年第三季全球治療性肉毒桿菌毒素產品系列淨銷售額達8.48億美元的報告也印證了這一點。

市場挑戰

全球痙攣治療市場面臨著巨大的限制，這主要是由於先進治療性介入，特別是肉毒桿菌注射和鞘內Baclofen幫浦等高昂費用所致。這些昂貴的治療方法給醫療系統和患者個人都帶來了沉重的經濟負擔。在許多地區，現有的健保報銷政策往往不足以完全涵蓋這些特殊生物製藥和醫療設備的高昂成本。這種經濟缺口常常迫使醫療服務提供者開立價格較低廉的口服非專利藥。雖然這些藥物易於取得，但它們在治療重度痙攣方面通常療效較差。

這種經濟差距嚴重限制了市場滲透率，尤其是在開發中國家，自付費用是一大障礙。基礎疾病帶來的沉重經濟負擔進一步加劇了這種情況。例如，世界卒中組織估計，到2024年，卒中造成的全球經濟損失將達到每年約8,900億美元。如此巨大的基本醫療保健成本使得支付方難以證明並核准額外的、昂貴的痙攣治療，從而直接導致先進解決方案的採用率下降，並最終限制了整個市場的產生收入和成長潛力。

市場趨勢

改變痙攣管理的關鍵趨勢之一是機器人輔助物理治療（CBT）技術的日益普及。這項技術能夠進行高強度、重複性的步態訓練，而這是單純的手法治療無法實現的。先進的外骨骼設備正擴大被引入臨床，為脊髓損傷和各種神經病變患者提供機械支撐，並促進其運動學習。醫保報銷環境的改善尤其推動了這種向自動化復原的轉變，使這些先進設備更容易被病患所接受。例如，Lifeward Ltd.報告稱，其ReWalk個人外骨骼在2024年的銷售額成長了130%，這一成長直接歸功於Medicare的覆蓋。

同時，穿戴式神經調節和生物回饋療法設備的普及正在改變醫療保健模式，將治療方式從間歇性的醫院就診轉變為持續的居家行動解決方案。這些非侵入式技術通常被設計成仿生穿戴設備，利用人工智慧提供功能性電刺激，從而即時精準地糾正步態模式並抑制肌肉痙攣。越來越多的醫生開立此類設備，清楚地表明了這些方便用戶使用型介面的快速市場滲透。例如，2025年9月，Cionic公司宣布其Neural Sleeve技術已被全國1500名醫生採用，證實了市場對高度適應性的穿戴式治療性介入的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肌肉脊髓市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物類型（Baclofen、肉毒桿菌、Diazepam、丹曲林鈉、其他）
  • 給藥途徑（口服、肌肉注射、其他）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美肌肉夾板市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲肌肉夾板市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區肌肉脊髓市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲肌肉夾板市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲肌肉扭傷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球肌肉夾板市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Ipsen SA
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global muscle spasticity market is projected to expand significantly, growing from USD 3.65 billion in 2025 to USD 5.41 billion by 2031, demonstrating a compound annual growth rate of 6.78%. This market encompasses a range of pharmaceutical treatments and medical devices specifically designed to alleviate involuntary muscle contractions, which are typically associated with various central nervous system disorders. Its growth is primarily fueled by the increasing global incidence of chronic neurological conditions, such as cerebral palsy and stroke, which necessitate ongoing therapeutic management to enhance patient mobility and quality of life.

For instance, the Multiple Sclerosis International Federation reported approximately 2.9 million individuals living with multiple sclerosis worldwide in 2024, creating a consistent demand for effective antispasmodic solutions. However, a major impediment to the market's broader expansion is the substantial cost of advanced therapies, including botulinum toxin injections and intrathecal baclofen pumps. These high expenses, combined with insufficient reimbursement policies in developing economies, restrict patient access to critical treatments and often lead healthcare providers to opt for more affordable, yet less effective, generic oral medications, thereby hindering revenue potential in these regions.

Market Driver

A primary catalyst for the muscle spasticity market's expansion is the increasing prevalence of chronic neurological disorders, which frequently result in spasticity following central nervous system damage. Conditions like stroke and traumatic brain injuries disrupt normal neural signaling, creating an urgent need for effective, long-term management strategies to prevent permanent muscle contractures. According to the World Health Organization's March 2024 study, neurological conditions collectively affect approximately 3.4 billion people globally, establishing them as a leading cause of disability and ensuring a sustained demand for therapeutic interventions.

For example, the National Spinal Cord Injury Statistical Center estimated around 305,000 cases of spinal cord injuries in the United States in 2024, a patient demographic heavily reliant on consistent antispasmodic care. Furthermore, the increasing adoption of botulinum toxin injectables represents a significant secondary driver, marking a clinical shift from systemic oral medications towards highly targeted focal therapies. These biologic treatments offer precise muscle relaxation with a reduced risk of systemic side effects, prompting increased utilization by specialists for refractory spasticity, as evidenced by AbbVie reporting global net revenues of $848 million for its therapeutic botulinum toxin portfolio in the third quarter of 2024.

Market Challenge

The global muscle spasticity market faces a significant restraint due to the prohibitive cost associated with advanced therapeutic interventions, particularly botulinum toxin injections and intrathecal baclofen pumps. These premium treatment modalities demand substantial financial commitment from both healthcare systems and individual patients. In numerous regions, existing reimbursement policies are often inadequate to fully cover the high expenses of these specialized biologics and medical devices. This financial gap frequently compels healthcare providers to prescribe more affordable generic oral medications, which, despite being accessible, are typically less effective in managing severe spasticity symptoms.

This economic disparity significantly limits market penetration, especially within developing economies where out-of-pocket expenses are a major barrier. The substantial economic burden of underlying conditions further exacerbates the situation; for instance, the World Stroke Organization estimated the global economic impact of stroke at approximately $890 billion annually in 2024. Such immense baseline healthcare costs make it challenging for payers to justify and approve additional high-cost spasticity therapies, directly reducing the adoption rates of advanced solutions and consequently restricting the market's overall revenue generation and growth potential.

Market Trends

A key trend reshaping spasticity management is the increasing adoption of robotic-assisted physical rehabilitation technologies, which enable high-intensity, repetitive gait training beyond what manual therapy can achieve. Advanced exoskeletons are increasingly being integrated into clinical practice to offer mechanical support and facilitate motor learning for patients suffering from spinal cord injuries and various neurological impairments. This shift towards automated rehabilitation is notably supported by improved reimbursement landscapes, which have significantly enhanced patient access to these sophisticated devices; for example, Lifeward Ltd. reported a 130% increase in ReWalk Personal Exoskeleton sales in 2024, directly attributing this growth to established Medicare coverage.

Concurrently, the proliferation of wearable neuromodulation and biofeedback devices is transforming care by moving it from intermittent clinical visits to continuous, home-based mobility solutions. These non-invasive technologies, often designed as bionic clothing, leverage artificial intelligence to deliver functional electrical stimulation that precisely corrects gait patterns and suppresses muscle spasms in real-time. The rapid market penetration of these user-friendly interfaces is clearly demonstrated by their expanding prescriber base; Cionic, for instance, announced in September 2025 that its Neural Sleeve technology had reached 1,500 prescribers nationwide, underscoring the robust demand for adaptive, wearable therapeutic interventions.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Ipsen S.A.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Spasticity Market, By Drug Type

• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

Muscle Spasticity Market, By Route of Administration

• Oral
• Intramuscular
• Others

Muscle Spasticity Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Muscle Spasticity Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.

Available Customizations:

Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Muscle Spasticity Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
  • 5.2.2. By Route of Administration (Oral, Intramuscular, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Muscle Spasticity Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Muscle Spasticity Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Muscle Spasticity Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Muscle Spasticity Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Muscle Spasticity Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Muscle Spasticity Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Muscle Spasticity Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Muscle Spasticity Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Muscle Spasticity Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Muscle Spasticity Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Muscle Spasticity Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Muscle Spasticity Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Muscle Spasticity Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Muscle Spasticity Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Muscle Spasticity Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Muscle Spasticity Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Muscle Spasticity Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Muscle Spasticity Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Muscle Spasticity Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Muscle Spasticity Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Muscle Spasticity Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Muscle Spasticity Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Muscle Spasticity Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Muscle Spasticity Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Muscle Spasticity Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Novartis AG
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Merck & Co., Inc.
• 15.6. Eli Lilly and Company
• 15.7. Bausch Health Companies Inc.
• 15.8. Ipsen S.A.
• 15.9. Sanofi S.A.
• 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer